ArticleBiochemistry and biophysics reports2026
Lipidomic profiling of PEX11β knockout T-REx 293 cells reveals lipid shifts suggesting potential metabolic perturbations.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxisomes function in reactive oxygen species (ROS) and lipid metabolism. Genetic defects in peroxisome biogenesis cause severe neurological disorders collectively termed peroxisome biogenesis disorders (PBDs). Dysregulated peroxisomes are also increasingly implicated in cancer and therapy resistance. Our comparative analysis of peroxin knockouts (PEX KO) in a human embryonic kidney-derived cell line by untargeted lipidomics reveals distinct lipid fingerprints across PEX KO conditions. PEX3 and PEX14 KO cell lines are highly enriched in very-long-chain fatty acids (VLCFAs) and depleted in ether- and plasmalogen-linked phospholipids. While they differ in the same lipids, PEX3 KO cells demonstrate stronger shifts from the wild-type profile than PEX14 KO cells. In contrast, PEX11β KO cells nearly match the wild-type lipid profile except for several highly enriched lipid analytes, most notably ceramides. These distinct metabolic adaptations are paralleled by the cell lines' divergent responses to glucose-6-phosphate dehydrogenase (G6PD) inhibition, suggesting PEX KO phenotype-specific differences in redox stress and NADPH source reliance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.